IntegraGen SA (ALINT.PA)
- Previous Close
0.5800 - Open
0.5800 - Bid --
- Ask --
- Day's Range
0.5701 - 0.6296 - 52 Week Range
0.4340 - 0.8600 - Volume
19,913 - Avg. Volume
2,546 - Market Cap (intraday)
4.137M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was incorporated in 2000 and is headquartered in Évry, France. IntegraGen SA operates as a subsidiary of OncoDNA SA.
integragen.comRecent News: ALINT.PA
View MorePerformance Overview: ALINT.PA
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALINT.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALINT.PA
View MoreValuation Measures
Market Cap
3.84M
Enterprise Value
2.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
2.03
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
39.18
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.94%
Return on Assets (ttm)
-7.47%
Return on Equity (ttm)
-13.59%
Revenue (ttm)
8.7M
Net Income Avi to Common (ttm)
-256k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.9M
Total Debt/Equity (mrq)
36.64%
Levered Free Cash Flow (ttm)
--